Updated efficacy, safety, and correlative analysis of a phase II trial in metastatic renal cell carcinoma with coordinated pembrolizumab and high dose IL-2.

Authors

Christopher W Guske, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

2-2025

Volume

43

Issue

5

Published In/Presented At

https://doi.org/10.1200/JCO.2025.43.5_suppl.554

Disciplines

Medical Education | Medicine and Health Sciences

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article